ArticleCureus2025
Randomized, Single-Blind Comparison of Two Different Flow Rates of Sevoflurane Anesthesia on Acute Kidney Injury.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProlonged sevoflurane-based low-flow anaesthesia (LFA) is often not advised for clinical use due to acute kidney injury (AKI) risk. However, LFA has multitudes of advantages, and surveys on anesthesia practice indicate that the use of LFA, even with sevoflurane, is on the rise. Literature on human studies is growing, but the recommendations for LFA have not changed, indicating the need for further evaluation. We aimed to evaluate the incidence of AKI with sevoflurane-based LFA with two different FGFs.
methodsThe current prospective, randomized, single-blind, parallel-arm study was conducted using sevoflurane-based LFA with two FGFs: group A (1000mL/min) and group B (600mL/min) with a targeted age-adjusted minimum alveolar concentration (MACage) of 1-1.2 enrolling adult participants undergoing elective surgeries of at least 120-minute anesthesia duration. Anesthesia management was standardized, and AKI classification was performed based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Further, spot urinary microalbumin, sodium (Na), potassium (K), protein, and spot albumin creatinine ratio (sACR) were evaluated and compared. A two-tailed p-value <0.05 was considered statistically significant.
resultsData from 65 (33 in the 1000mL and 32 in the 600mL group) were evaluated. No AKI was noted in either group. The anesthesia duration ranged from 120 to 780 minutes (median 200, interquartile range 260-180, with mean 230.9, and 95% confidence 202.5-259.3 minutes). Spot urine microalbumin was significantly higher at two to four hours postoperatively than at the preoperative level, but the rise was similar in both groups. By 24 hours, the level declined significantly and remained at a slightly higher level than the preoperative value, which further reduced to a somewhat lower level than the preoperative value by 48 hours. Only one patient in the 1000mL/min group had sACR >66.7 μg/mg.
conclusionSevoflurane-based LFA with an FGF of 600mL/min is safe and comparable to the FGF of 1000mL/min for surgeries. Transient urinary microalbumin and sACR changes occur, which settle within 24 to 48 hours; no impact on urine output and AKI was noted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.